Delivery Order SPE2DB20D3103-SPE2DB25FP8Z8
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $87,619.50 to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 mL vials. This contract is a firm fixed price delivery order with no set-aside designation, issued competitively on June 11, 2025, with an ultimate completion date of July 3, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a $50,978.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 ml vials. The award was made on September 11, 2025, with an ultimate completion date of October 2, 2025, and the product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a continuation of the company's...
- The Defense Logistics Agency awarded a $52,571.70 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Ultomiris 1,100 mg/11 ml vials. This firm fixed-price, competitively awarded contract is scheduled for completion by October 15, 2025, with performance occurring at the vendor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The U.S. Department of Defense Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $102,754.09 for Ultomiris 300 mg/3 mL vials on September 15, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency awarded a $26,285.93 delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 300 mg/3 mL vials on July 30, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and identifies AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $9,558.52 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ultomiris 300 mg/3 ml vials. This non-competitive delivery order, with an ultimate completion date of September 29, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $52,571.70 to AmerisourceBergen Drug Corp for the supply of Ultomiris (1,100 mg/11 mL vial), a pharmaceutical product for military healthcare needs. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 6, 2025, performed from the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ultomiris (pegtibatimab alfa), a specialty pharmaceutical product, with a ceiling value of $26,285.85. This firm fixed-price delivery order is set to be completed by August 14, 2025, and represents performance at the vendor's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation,...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $26,285.93 by the Defense Logistics Agency on July 18, 2025, for the supply of Ultomiris 300 mg/3 ml vials. This competitively awarded, firm fixed-price contract has no set-aside designation and is scheduled for completion by August 8, 2025. The award represents a child delivery order under AmerisourceBergen's broader relationship with the DLA, leveraging the company's established...
- This federal contract award is for the delivery of Ultomiris, a pharmaceutical product, to the Defense Logistics Agency (DLA). The fixed-price contract, valued at $48,444.54, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of November 7, 2024 and was awarded on October 17, 2024. The contract is a delivery order and does not have a set-aside designation, indicating open competition....
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8Z8Delivery Order
The Defense Logistics Agency awarded a $131,429.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 mL vials. This contract, issued on August 15, 2025, with an ultimate completion date of September 8, 2025, represents a non-set-aside competitive award supporting federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and veteran healthcare systems through its extensive federal contract portfolio. This delivery order operates under AmerisourceBergen Drug Corp's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. This prime IDC vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialized medications and vaccines across multiple therapeutic domains. The award demonstrates AmerisourceBergen Drug Corp's continued capability to meet federal medical supply requirements through open competition and its role as a primary vendor in the Defense Logistics Agency's pharmaceutical supply chain supporting the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $131.4k | 8/15/25 |